LRRK2 inhibitor fails in Parkinson trial
A closely watched experimental Parkinson’s treatment has failed its first major clinical test.
The treatment from Biogen and Denali Therapeutics targeted the protein LRRK2. Mutations in the gene encoding this protein are among the best-known genetic risk factors for Parkinson’s disease. Researchers first identified that link in 2004. Since then, inhibiting overactive LRRK2 has been a widely pursued direction in Parkinson’s research.
In the randomized trial, 648 adults with Parkinson’s received either a placebo or the LRRK2 inhibitor. The drug did not slow decline. That is a substantial setback for an approach that generated significant excitement for years.
What the failure says about the strategy
One possible explanation is that LRRK2 mutations are relevant only in a subset of Parkinson’s patients. Most participants in the trial likely did not carry a LRRK2 mutation. Inhibiting the protein provides little benefit if it is not the cause of a patient’s disease. The researchers are now analyzing whether any subgroups showed a response.
The failure fits a broader pattern. Parkinson’s is a heterogeneous disease. Different patients have different underlying causes, even when their symptoms appear similar. Therapies aimed at a single molecular target rarely work for everyone.
Implications for future research
The result increases pressure to better stratify Parkinson’s patients by genetic profile before assigning them to trials. An LRRK2 inhibitor could still be meaningful for patients who specifically carry a LRRK2 mutation. That subgroup is smaller but genetically better defined.
For the broader Parkinson’s community, this is disappointing news. But the outcome also sharpens the direction: targeted treatment based on genetics looks increasingly unavoidable as the next step.
Want to research this yourself?
Search for terms like: LRRK2 Parkinson clinical trial